Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amrutanjan Health Care Limited reported audited standalone financial results for Q4 and year ended March 31, 2026. Revenue from operations grew 11.23% year-on-year to ₹50,255.27 lakhs (FY26) from ₹45,181.63 lakhs (FY25). Profit after tax increased 13.93% to ₹5,791.78 lakhs from ₹5,083.47 lakhs. Basic and diluted EPS stood at ₹20.03 per share versus ₹17.58 in the prior year. The Board recommended a final dividend of ₹2.90 per share (face value ₹1). Exceptional items of ₹885.67 lakhs included a ₹760.50 lakhs provision for retrospective lease rent revision (Tamil Nadu government matter) and ₹125.17 lakhs impact from new labour codes. The auditor issued an unmodified (clean) opinion. The Board also approved appointment of a new Independent Director, re-appointment of another, and rolling out of a revised ESOP 2 scheme.
The company delivered double-digit revenue and profit growth with strong cash generation from operations at ₹3,596.77 lakhs. The clean audit and dividend declaration are positives. However, the one-time exceptional charges (₹885.67 lakhs) are a one-time hit to profitability that investors should note. The stock could see a modest positive reaction given steady operational performance.